Amendments to the Claims

1. (currently amended) A compound represented by formula (I); ~~or a pharmaceutically acceptable salt or a prodrug derivative thereof:~~



(I)



(I)

wherein;

R and R' are independently C_1-C_5 alkyl, ~~C_1-C_5 fluoroalkyl,~~ or together R and R' form a ~~substituted or unsubstituted,~~ saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;

R_{PH} is hydrogen or methyl;

R1 and R2 are independently ~~selected from the group consisting of~~ hydrogen, halo, or C_1-C_5 alkyl;~~, C_1-C_5 fluoroalkyl, -O-C_1-C_5 alkyl, -S-C_1-C_5 alkyl, -O-C_1-C_5 fluoroalkyl, -CN, -NO_2, acetyl, -S-C_1-C_5 fluoroalkyl, C_2-C_5 alkenyl, C_3-C_5 cycloalkyl, and C_3-C_5 cycloalkenyl;~~

L_1 is -$(CH_2)_m$-O-;

~~and~~ L_2 is -$(CH_2)_m$CH(OH)- or -$(CH_2)_m$C(O)- ~~; and L_3 are independently divalent linking groups independently selected from the group consisting of~~



where m is 0, 1 or 2, ~~X_1 is oxygen or sulfur, and each R40 is independently hydrogen, C_1-C_5 alkyl, or C_1-C_5 fluoroalkyl;~~

R_B is

a branched C_3-C_5 alkyl,

~~3-methyl-3-hydroxypentyl,~~

~~3-methyl-3-hydroxypentenyl,~~

~~3-methyl-3-hydroxypentynyl,~~

~~3-ethyl-3-hydroxypentyl,~~

~~3-ethyl-3-hydroxypentenyl,~~

~~3-ethyl-3-hydroxypentynyl,~~

~~3-ethyl-3-hydroxy-4-methylpentyl,~~

~~3-ethyl-3-hydroxy-4-methylpentenyl,~~

~~3-ethyl-3-hydroxy-4-methylpentynyl,~~

~~3-propyl-3-hydroxypentyl,~~

~~3-propyl-3-hydroxypentenyl,~~

~~3-propyl-3-hydroxypentynyl,~~

~~1-hydroxy-2-methyl-1-(methylethyl)propyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentenyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentynyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentenyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentynyl,~~

~~4,4-dimethyl-3-hydroxypropyl,~~

~~1-hydroxycyclopentenyl,~~

~~1-hydroxycyclohexenyl,~~

~~1-hydroxycycloheptenyl,~~

~~1-hydroxycyclooctenyl,~~

~~1-hydroxycyclopropyl,~~

~~1-hydroxycyclobutyl,~~

~~1-hydroxycyclopentyl,~~

~~1-hydroxycyclohexyl,~~

~~1-hydroxycycloheptyl, or~~

~~1-hydroxycyclooctyl;~~

~~provided, however, that when~~

~~R_B is~~

~~3-methyl-3-hydroxypentyl,~~

~~3-methyl-3-hydroxypentenyl,~~

~~3-methyl-3-hydroxypentynyl,~~

~~3-ethyl-3-hydroxypentyl,~~

~~3-ethyl-3-hydroxypentenyl,~~

~~3-ethyl-3-hydroxypentynyl,~~

~~4,4-dimethyl-3-hydroxypropyl,~~

~~3-ethyl-3-hydroxy-4-methylpentyl,~~

~~3-ethyl-3-hydroxy-4-methylpentenyl,~~

~~3-ethyl-3-hydroxy-4-methylpentynyl,~~

~~3-propyl-3-hydroxypentyl,~~

~~3-propyl-3-hydroxypentenyl,~~

~~3-propyl-3-hydroxypentynyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentenyl,~~

~~3-methyl-3-hydroxy-4,4-dimethylpentyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentynyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentenyl,~~

~~3-ethyl-3-hydroxy-4,4-dimethylpentynyl, or~~

~~1-hydroxy-2-methyl-1-(methylethyl)propyl;~~

~~then L_1 and L_2 combine as a bond; and~~

R_C is

-O-SO_2-(R50)

where R50 is

-C_{1-3}alkyl, -CF_3, or -$(CH_2)_{1-2}CF_3$;

~~-S-C_{1-3}alkyl, -SO_2-C_{1-3}alkyl,~~

~~-$(CH_2)_{1-2}$C(O)NHMe,~~

~~-$(CH_2)_{1-2}$-CO_2H; or~~

-NH-SO_2-(R50)

where R50 is

-C_{1-3}alkyl, -CF_3, or -$(CH_2)_{1-2}CF_3$,

~~-S-C_{1-3}alkyl, -SO_2-C_{1-3}alkyl,~~

~~$-(CH_2)_{1-2}-CO_2H$,~~

~~$-(CH_2)_{1-2}C(O)NHMe$, or~~

$-N(CH_3)-SO_2-C_{1-2}$alkyl; or

$-N(SO_2R51)_2$

where each R51 is independently,

$-C_{1-3}$alkyl, $-CF_3$, or $-(CH_2)_{1-2}CF_3$,

~~$-(CH_2)_{1-2}C(O)NHMe$,~~

~~$-S-C_{1-3}$alkyl, $-SO_2-C_{1-3}$alkyl, or~~

~~$-(CH_2)_{1-2}-CO_2H$~~.

2. (currently amended) A compound ~~or pharmaceutically acceptable salt or prodrug thereof~~ according to Claim 1 wherein R_{PH} is hydrogen.

3-4. (canceled)

5. (currently amended) A compound ~~or a pharmaceutically acceptable salts or an ester prodrug derivative thereof~~ according to Claim 1 represented by the structural formulae M-1 to M-31 as follows:

M-1)



,

M-2)



,

M-3)



,

M-4)



,

M-5)



,

M-6)



,

M-7)



,

M-8)



,

M-9)



,

M-11)



,

M-12)



,

M-13)



,

M-14)



,

M-15)



,

M-16)



,

M-17)



,

M-18)



,

M-19)



,

M-20)



,

M-22)



,

M-23)



,

M-24)



,

M-25)



,

M-28)



,

M-29)



,

M-30)



, or

M-31)



.

6. (currently amended) A compound ~~or a pharmaceutically acceptable salt or an ester prodrug derivative thereof according to Claim 1~~ represented by the structural formulae M-32 to M-50 as follows:

M-32)



,

M-34)



,

M-35)



,

M-36)



,

M-37)



,

M-38)



,

M-39)



,

M-40)



,

M-41)



,

M-42)



,

M-43)



,

M-44)



,

M-45)



,

M-46)



,

M-47)



,

M-48)



,

M-49)



, or

M-50)



7. (canceled)

8. (Currently Amended) A compound ~~according to Claim 1~~ represented by ~~the~~ a formula below:





, or



9-15. (canceled)

16. (previously presented) A pharmaceutical formulation comprising the compound according to Claim 1 together with a pharmaceutically acceptable carrier or diluent.

17-18. (canceled)

19. (original) A formulation for treating psoriasis comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 1;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

a. topical glucocorticoids ,

b. salicylic acid,

c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

20. (canceled)

21. (currently amended, withdrawn) A method of treating a mammal for ~~to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host graft rejection, Hypercalcemia , Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia,~~ Osteoporosis, ~~Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer,~~ Psoriasis, ~~Renal osteodystrophy, Rheumatoid arthritis,~~ Scleroderma, ~~or~~ seborrheic dermatitis ~~Skin cancer, Systemic lupus erythematosus, Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles;~~ wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1.

22. (withdrawn) The method of claim 21 for the treatment of psoriasis.

23. (withdrawn) The method of claim 21 for the treatment of osteoporosis.

24-25. (canceled)

26. (currently amended, withdrawn) A method of treating ~~or preventing disease~~ states

mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 1.

27-32. (canceled)

33. (new) A compound represented by formula (II) or a pharmaceutically acceptable salt thereof:



(II)

wherein;

R2 and R2' are independently methyl or ethyl;

R21 and R22 are independently selected from: hydrogen, methyl, ethyl, or -Cl,

$R2_B$ is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and

$R2_C$ is



where Q is –O- or –NH-.

34. (new) A compound represented by formula (III) or a pharmaceutically acceptable salt thereof:



(III)

wherein;

R3 and R3' are independently methyl or ethyl;

R31 and R32 are independently selected from: hydrogen, methyl, ethyl, or -Cl,

$R3_B$ is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and

$R3_C$ is



or



35. (new) A compound represented by a formula below:



36. (new) A compound represented by a formula below:



37. (new) A compound represented by a formula below:



38. (new) A pharmaceutical formulation comprising the compound according to one of claims 35, 36 or 37 together with a pharmaceutically acceptable carrier or diluent.

39. (new) A method of treating a mammal for Osteoporosis, Psoriasis, Scleroderma, or seborrheic dermatitis wherein the method comprises administering a pharmaceutically effective amount of at least the compound of according to one of claims 35, 36, or 37.

40. (new) The method of claim 39 for the treatment of psoriasis.

41. (new) The method of claim 39 for the treatment of osteoporosis.